ERK 2 Inhibitors
Santa Cruz Biotechnology now offers a broad range of ERK 2 Inhibitors. Mitogen-activated protein kinase (MAPK) signaling pathways involve two closely related MAP kinases, known as extracellular-signal-related kinase 1 (ERK 1, p44) and 2 (ERK 2, p42). Growth factors, steroid hormones, G protein-coupled receptor ligands, and neurotransmitters can initiate MAPK signaling pathways. Activation of ERK1 and ERK2 requires phosphorylation by upstream kinases such as MAP kinase kinase (MEK), MEK kinase and Raf-1. ERK 2 Inhibitors offered by Santa Cruz inhibit ERK 2 and, in some cases, other proliferation and transcription regulation related proteins. View detailed ERK 2 Inhibitor specifications, including ERK 2 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
SEE ALSO...
Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $363.00 | 5 | |
SCH772984 functions as a selective inhibitor of ERK 2, showcasing a distinct binding profile that promotes the stabilization of the inactive form of the enzyme. Its unique interactions involve key hydrophobic pockets and critical amino acid residues, which hinder ATP binding and substrate access. This selective inhibition alters downstream signaling pathways, providing insights into the regulatory mechanisms of cellular proliferation and differentiation. Its kinetic properties reveal a rapid onset of action, underscoring its potential for precise modulation of ERK 2 activity. | ||||||
GDC0994 | 1453848-26-4 | sc-507297 | 10 mg | $130.00 | ||
A potent and selective inhibitor of ERK 2, shown to express anit-cancer properties. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
An available ERK 2 inhibitor, mainly explored for its anti-cancer properties. | ||||||
CCT196969 | 1163719-56-9 | sc-507303 | 5 mg | $135.00 | ||
A highly selective inhibitor of ERK 2, currently being studied. | ||||||